ARS Pharmaceuticals Stockholders With Large Losses Should Contact Robbins LLP
Robbins LLP reminds ARS Pharmaceuticals Inc. stockholders who suffered significant losses to contact them regarding a securities class action before the October 5, 2026 deadline.
Law firm Robbins LLP has notified shareholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) that they must contact the firm before the October 5, 2026 deadline concerning a securities class action lawsuit.
The lawsuit covers all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. securities between March 9, 2026, and June 24, 2026. The company is accused of making misleading or false statements and omitting material information in its press releases and reports.
Specifically, the complaint alleges that ARS Pharmaceuticals provided inaccurate information regarding the commercial potential and future sales of the company's products. Investors allegedly purchased shares on false pretenses and suffered substantial losses when the company's true situation came to light.
Robbins LLP specializes in securities litigation and aims to recover damages for investors who incurred losses due to the company's actions. Further details can be found on the firm's website or by contacting Robbins LLP directly.